Featured Research

from universities, journals, and other organizations

New class of drug kills lymphoma cells

Date:
April 14, 2010
Source:
Cell Press
Summary:
Scientists are one step closer to developing a targeted therapy for lymphoma. New research identifies a specific small-molecule inhibitor that was nontoxic in animal experiments and could kill human lymphoma cells.

Scientists are one step closer to developing a targeted therapy for lymphoma. New research, published by Cell Press in the April 13th issue of the journal Cancer Cell, identifies a specific small-molecule inhibitor that was nontoxic in animal experiments and could kill human lymphoma cells.

BCL6 is the most commonly involved oncogene in diffuse large B cell lymphomas (DLBCL). Previous work has shown that BCL6 is required for survival of lymphoma cells and that blockade of the gene potently kills DLBCL cells. However, although BCL6 it a very attractive therapeutic target, it has not been considered to be particularly amenable to targeting with small molecules.

"Like many oncogenes, BCL6 is a transcription factor," says senior study author Dr. Ari Melnick from Weill Cornell Medical College in New York. "Transcription factors like BCL6 usually exert their actions through extensive interactions with other proteins. In general, small molecule inhibitors with the potential to become drug candidates have been considered not likely to effectively disrupt protein-protein interactions."

Dr. Melnick and colleagues used structure-based strategies to determine where the best point of attack would be to disrupt the activity of BCL6. Using computer-aided drug design combined with functional assays, the researchers identified small molecule compounds that specifically interacted with BCL6 at an exposed groove within the BCL6 BTB domain. The researchers were interested in this specific part of BCL6 because it is the binding site of cofactors required for BCL6 to carry out its cancer-causing functions.

One of the compounds that they identified, called 79-6, bound specifically to the BTB groove and effectively killed BCL6-positive DLBCL cell lines. Further, 79-6 markedly reduced BCL6-dependent tumors in mice that had received transplants of human lymphoma cells and specifically killed primary human DLBCL cells.

"Our work demonstrates that oncogenic transcriptional repressors can be therapeutically targeted with small molecules and presents a rationally designed therapy approach for treatment of lymphomas," concludes Dr. Melnick. "Future efforts will be taken to systematically improve the therapeutic potential of these compounds with the goal of developing BCL6 targeted therapy for DLBCL."

The researchers include Leandro C. Cerchietti, Weill Cornell Medical College, Cornell University, New York, NY; Alexandru F. Ghetu, Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Toronto, Canada; Xiao Zhu, University of Maryland, Baltimore, MD; Gustavo F. Da Silva, University of Maryland, Baltimore, MD; Shijun Zhong, University of Maryland, Baltimore, MD; Marilyn Matthews, University of Maryland, Baltimore, MD; Karen L. Bunting, Weill Cornell Medical College, Cornell University, New York, NY; Jose M. Polo, Albert Einstein College of Medicine, Bronx, NY; Christophe Fares, Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Toronto, Canada; Cheryl H. Arrowsmith, Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Toronto, Canada, University of Toronto, Toronto, Canada; Shao Ning Yang, Weill Cornell Medical College, Cornell University, New York, NY; Monica Garcia, Weill Cornell Medical College, Cornell University, New York, NY; Andrew Coop, University of Maryland, Baltimore, MD; Alexander D. MacKerell, Jr., University of Maryland, Baltimore, MD; Gilbert G. Prive, Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Toronto, Canada, University of Toronto, Toronto, Canada; and Ari Melnick, Weill Cornell Medical College, Cornell University, New York, NY.


Story Source:

The above story is based on materials provided by Cell Press. Note: Materials may be edited for content and length.


Journal Reference:

  1. Leandro C. Cerchietti, Alexandru F. Ghetu, Xiao Zhu, Gustavo F. Da Silva, Shijun Zhong, Marilyn Matthews, Karen L. Bunting, Jose M. Polo, Christophe Farθs, Cheryl H. Arrowsmith, Shao Ning Yang, Monica Garcia, Andrew Coop, Alexander D. MacKerell, Gilbert G. Privι, Ari Melnick. A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo. Cancer Cell, 2010; 17 (4): 400-411 DOI: 10.1016/j.ccr.2009.12.050

Cite This Page:

Cell Press. "New class of drug kills lymphoma cells." ScienceDaily. ScienceDaily, 14 April 2010. <www.sciencedaily.com/releases/2010/04/100412124955.htm>.
Cell Press. (2010, April 14). New class of drug kills lymphoma cells. ScienceDaily. Retrieved October 23, 2014 from www.sciencedaily.com/releases/2010/04/100412124955.htm
Cell Press. "New class of drug kills lymphoma cells." ScienceDaily. www.sciencedaily.com/releases/2010/04/100412124955.htm (accessed October 23, 2014).

Share This



More Health & Medicine News

Thursday, October 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Fears Keep Guinea Hospitals Empty

Ebola Fears Keep Guinea Hospitals Empty

AP (Oct. 23, 2014) — Fears of Ebola are keeping doctors and patients alike away from hospitals in the West African nation of Guinea. (Oct. 23) Video provided by AP
Powered by NewsLook.com
Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) — Is your child ready? Video provided by Working Mother
Powered by NewsLook.com
U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

Newsy (Oct. 22, 2014) — Now that the U.S. is restricting travel from West Africa, some are dropping questions about a travel ban and instead asking about visa bans. Video provided by Newsy
Powered by NewsLook.com
More People Diagnosed With TB In 2013, But There's Good News

More People Diagnosed With TB In 2013, But There's Good News

Newsy (Oct. 22, 2014) — The World Health Organizations says TB numbers rose in 2013, but it's partly due to better detection and more survivors. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins